Join this workshop to navigate the engineering trade‑offs required to unlock the potential of costimulatory engagers in solid tumors.

• Identifying tumour targets and biological contexts where conditional activation can meaningfully improve safety, selectivity, and therapeutic index
• Evaluating masking strategies across T cell engager architectures, including associated efficacy and development trade‑offs
• Designing protease‑ and microenvironment‑responsive systems by selecting robust cleavable linkers, pH‑sensitive elements, and stable molecular building blocks suitable for tumour‑localized activation
• Defining pharmacokinetic and preclinical data requirements needed to justify the added complexity of conditionally activated T cell engagers relative to conventional formats